New CAPS pill shows promise in tiny early trial
NCT ID NCT07247266
First seen Jan 04, 2026 · Last updated May 10, 2026 · Updated 18 times
Summary
This study tests an experimental drug called JTE-162 in 5 adults with CAPS, a rare genetic disease that causes fever, rash, and joint pain. Participants take one pill daily for 2 weeks. Researchers will check if the drug reduces inflammation and symptoms safely. This is an early-phase trial, so the main goal is safety and finding the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gordon Sussman Clinical Research Inc.
RECRUITINGNorth York, Ontario, M3B 3S6, Canada
Conditions
Explore the condition pages connected to this study.